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Beneficial effects of increased lysozyme levels in Alzheimer's disease modelled
in Drosophila melanogaster
Abstract
Genetic polymorphisms of immune genes that associate with higher risk to develop Alzheimer's disease
(AD) have led to an increased research interest on the involvement of the immune system in AD
pathogenesis. A link between amyloid pathology and immune gene expression was suggested in a
genome-wide gene expression study of transgenic amyloid mouse models. In this study, the gene
expression of lysozyme, a major player in the innate immune system, was found to be increased in a
comparable pattern as the amyloid pathology developed in transgenic mouse models of AD. A similar
pattern was seen at protein levels of lysozyme in human AD brain and CSF, but this lysozyme pattern was
not seen in a tau transgenic mouse model. Lysozyme was demonstrated to be beneficial for different
Drosophila melanogaster models of AD. In flies that expressed Aβ1-42 or AβPP together with BACE1 in
the eyes, the rough eye phenotype indicative of toxicity was completely rescued by coexpression of
lysozyme. In Drosophila flies bearing the Aβ1-42 variant with the Arctic gene mutation, lysozyme
increased the fly survival and decreased locomotor dysfunction dose dependently. An interaction between
lysozyme and Aβ1-42 in the Drosophila eye was discovered. We propose that the increased levels of
lysozyme, seen in mouse models of AD and in human AD cases, were triggered by Aβ1-42 and caused a
beneficial effect by binding of lysozyme to toxic species of Aβ1-42, which prevented these from exerting
their toxic effects. These results emphasize the possibility of lysozyme as biomarker and therapeutic
target for AD.
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Genetic polymorphisms of immune genes that associate with higher risk to
develop Alzheimer’s disease (AD) have led to an increased research interest
on the involvement of the immune system in AD pathogenesis. A link
between amyloid pathology and immune gene expression was suggested in
a genome-wide gene expression study of transgenic amyloid mouse models.
In this study, the gene expression of lysozyme, a major player in the innate
immune system, was found to be increased in a comparable pattern as the
amyloid pathology developed in transgenic mouse models of AD. A similar
pattern was seen at protein levels of lysozyme in human AD brain and
CSF, but this lysozyme pattern was not seen in a tau transgenic mouse
model. Lysozyme was demonstrated to be beneficial for different Drosophila melanogaster models of AD. In flies that expressed Ab1-42 or AbPP
together with BACE1 in the eyes, the rough eye phenotype indicative of
toxicity was completely rescued by coexpression of lysozyme. In Drosophila
flies bearing the Ab1-42 variant with the Arctic gene mutation, lysozyme
increased the fly survival and decreased locomotor dysfunction dose dependently. An interaction between lysozyme and Ab1-42 in the Drosophila eye
was discovered. We propose that the increased levels of lysozyme, seen in
mouse models of AD and in human AD cases, were triggered by Ab1-42
and caused a beneficial effect by binding of lysozyme to toxic species of
Ab1-42, which prevented these from exerting their toxic effects. These
results emphasize the possibility of lysozyme as biomarker and therapeutic
target for AD.

doi:10.1111/febs.13830

Abbreviations
AD, Alzheimer’s disease; Ab, amyloid-b; AbPP, amyloid-b precursor protein; BACE1, b-site AbPP-cleaving enzyme 1; CSF, cerebrospinal
fluid; PSEN1, presenilin 1; WT, wild-type.
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Lysozyme prevents Ab-toxicity

Introduction
Two of the main pathological hallmarks of Alzheimer’s disease (AD) are extracellular accumulation of
amyloid plaques, which consists of amyloid-b (Ab)
peptides, and intracellular neurofibrillary tangles composed of hyperphosphorylated tau [1]. The amyloid
plaques were previously considered the foremost neurotoxic agents in AD, but increasing evidence suggests
that small diffusible Ab aggregates (referred to as oligomers) are the principal cytotoxic species as these
correlate better with synaptic loss and cognitive
impairment than the plaques [2]. Ab peptides are
produced from sequential cleavage of the amyloid-b
precursor protein (AbPP) by b-secretase activity of the
b-site AbPP-cleaving enzyme 1 (BACE1) and the csecreatase complex, where presenilin 1 (PSEN1) is the
catalytic subunit [3]. Although Ab1-40 is the predominant secreted form, the longer Ab1-42 has a more
prominent part in AD as it is more aggregation prone
and forms toxic oligomers more easily [4]. Besides Ab
and tau, it is well established that neuroinflammation
is involved in AD. Activated astrocytes and microglia
cells surround Ab plaques together with various
inflammatory mediators [5,6]. In addition, genetic
studies show upregulation of several genes involved in
inflammation, especially complement activation and
prostaglandin synthesis, during incipient AD [7] and
there is data which demonstrate inflammatory
processes before tangles and neurodegeneration are
apparent [8]. However, microglial activation also
demonstrates a protective function of a triggered
immune response in AD, as microglial activation
mediates phagocytosis and clearance of Ab [9].
Lysozyme, which belongs to the innate immune system, is upregulated in cerebrospinal fluid (CSF) from
AD patients and inhibits the formation of toxic Ab oligomers [10–12]. Lysozyme overexpression in Ab transgenic Drosophila melanogaster rescues both the survival
and the activity of the Ab flies [10]. Lysozyme is a glucoside hydrolase able to hydrolyse peptidoglycans
found in the cell walls of bacteria [13]. It is secreted

from macrophages and microglia, and it is abundant in
various secretions such as tears, saliva, milk and CSF
[14]. The aim of this study was to further investigate
the implication of lysozyme in AD. Lysozyme gene
expression was investigated using a database of a genome-wide gene expression study of wild-type (WT) and
five mouse models of AD (mutant human AbPP,
mutant human PSEN1, homozygous and heterozygous
expressed AbPP–PSEN1 and mutant human TAU)
[15], and a database of AD patient brain tissue [16].
The levels of lysozyme protein were investigated in
brain tissue from transgenic AD mice and AD patients.
An increased lysozyme expression was found both at
mRNA and protein level in AD brain tissue of both
mice and humans. In order to investigate the impact of
lysozyme expression during AD, three different Drosophila models of AD were used. Beneficial effects of
lysozyme in these different Drosophila models were discovered; in flies that expressed Ab1-42 individually or
AbPP together with BACE1 (AbPP–BACE1) in the fly
eyes, the AD phenotype was completely rescued by
lysozyme. In flies carrying the highly toxic Ab peptide
with the Arctic mutation (E22G), lysozyme increased
the fly survival and improved the locomotor behaviour
in a dose-dependent manner. These results imply that
lysozyme has a protective effect on Ab toxicity and
could function as a new therapeutic strategy for AD.

Results
Lysozyme is increased in brains of transgenic AD
mice
To investigate whether the mRNA expression of lysozyme is changed during AD progression, we used data
from the publicly available database www.mouseac.
com on five different amyloid or tau mouse dementia
models. The mouse models were analysed at the ages
2, 4, 8 and 18 months [15]. Homozygous and
heterozygous expression of human AbPP, with the
Swedish mutation in combination with mutant human
PSEN1 (AbPP–PSEN1), leads to plaque formation at

Fig. 1. Lysozyme mRNA expression is increased in brains of transgenic AD mice. (A–C) Lysozyme mRNA expression (LYZ) in the cortex,
hippocampus and cerebellum of wild-type (WT) mice and amyloid transgenic mice expressing human AbPP or human PSEN1 or both genes
homo- or heterozygously (HOM_AbPP–PSEN1 and HET_AbPP–PSEN1) at 2, 4, 8 and 18 months of age. Significant increases of lysozyme in
HOM_AbPP–PSEN1 and HET_AbPP–PSEN1 compared with WT mice are denoted with asterix (*). Significant differences were determined
by two-way ANOVA with Tukey’s post hoc test, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. Mean and SD are presented at the different ages,
n = 4. (D–F) Lysozyme mRNA expression in the cortex, hippocampus and cerebellum in tau transgenic mice at 2, 4, 8 and 18 months of
age. Significant increases of lysozyme in TAU mice compared with WT mice are denoted with asterix (*). Significant differences were
determined by two-way ANOVA with Tukey’s post hoc test. Mean and SD are presented at the different ages, n = 4. (G,H) Correlation
analysis of lysozyme mRNA expression and Ab pathology in the cortex and hippocampus of homozygous or heterozygous AbPP–PSEN1
mice and AbPP mice using the Pearson correlation coefficient. (I) Correlation analysis of lysozyme mRNA expression and tau pathology in
cortex and hippocampus of tau transgenic mice using nonlinear regression.
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4 and 8 months, respectively, mutant AbPP expressed
separately leads to plaques first at 18 months and
mutant PSEN1 expressed separately has no plaque
pathology. The mutant human heterozygous TAU
mice demonstrate tangles at 8 months. The gene
expression of lysozyme in the homozygous AbPP–
PSEN1 mice was found to be significantly increased at
4 months in cortex (Fig. 1A) and hippocampus
(Fig. 1B) and in heterozygous AbPP–PSEN1 mice at
8 months compared to WT mice (Fig. 1A,B). Lysozyme levels were unchanged in cerebellum of both
homozygous and heterozygous AbPP–PSEN1 mice
(Fig. 1C). In AbPP mice, there was a trend of
increased lysozyme gene expression in cortex at
18 months, but not in hippocampus and no change
was detected in PSEN1 mice (Fig. 1A–C). We next
investigated the correlation between lysozyme gene
expression and Ab pathology in the cortex (Fig. 1G)
and hippocampus (Fig. 1H) of these mice. Both
heterozygous and homozygous AbPP–PSEN1 mice
showed a strong and significant linear correlation in
the cortex (r = 0.91 and 0.94 respectively) and in hippocampus (r = 0.86 and 0.95 respectively) (Fig. 1G,
H). Mice only expressing AbPP exhibited a strong
and significant correlation as well, both in cortex and
hippocampus, albeit weaker than for the double transgenic mice (r = 0.74 and 0.77 respectively) (Fig. 1G,
H). Tau transgenic mice showed an increase in lysozyme expression in cortex (Fig. 1D) and hippocampus
(Fig. 1E) only after 18 months. In the cerebellum of
the tau transgenic mice, no change in lysozyme gene
expression was detected (Fig. 1F). A sigmoid correlation relationship between lysozyme levels and tau
pathology was demonstrated in hippocampus (Fig. 1I;
R2 = 0.81), while this sigmoid correlation relationship
was weaker in cortex (Fig. 1I; R2 = 0.52). These
results demonstrate that the increase of Ab plaque
pathology can trigger lysozyme expression in the AD
mice brain, while tau pathology has no immediate
impact on lysozyme expression.
Next, lysozyme protein levels in WT and transgenic
mice, harbouring PS1 and the AbPPSwe mutations,
were investigated using western blot. AbPP-mutated
mice had an increased protein expression of Ab and of
lysozyme as compared to WT mice, which is consistent
with the mRNA expression analysis of lysozyme
(Fig. 2A,B). To study whether lysozyme and Ab colocalized in plaques, immunohistochemistry was performed on frozen tissue from mice with the AbPPSwe
mutation. Double-labelling with antibodies against
lysozyme and Ab showed that lysozyme localized
within the plaque as scattered dots (Fig. 2C).

WT
AβPP

4

**

2

0
Lyz

Aβ

C

5 μm

Fig. 2. Lysozyme protein expression is increased in brains of
transgenic AD mice. (A) Representative western blot of brain
homogenates from 12-month-old WT and AbPP transgenic mice
analysed for lysozyme, Ab and b-actin. (B) Densitometric
quantification of the western blot. Significant differences were
determined by Student’s t-test. Error bars represent mean  SD,
n = 4. (C) Immunohistochemistry of brain tissue prepared from 15month-old transgenic AbPPSwe mice, stained with 6E10 antibody
(brown) and anti-lysozyme (green). The white box shows one
single amyloid plaque in magnification. Lysozyme is present inside
the plaque (white arrow). Green circular structures (black arrow)
are cells stained with intracellular lysozyme.

Lysozyme is increased in the human AD brain
To study if the increased lysozyme mRNA expression
levels in AD mice also applied to human AD patients,
a database with data from autopsied tissues from
visual cortex, dorsolateral prefrontal cortex and
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cerebellum was used [16]. The mRNA expression of
lysozyme was significantly increased in visual cortex
and prefrontal cortex of AD patients compared to
control, but no difference was seen in cerebellum
(Fig. 3A). To study if the protein expression levels of
lysozyme were affected in AD, human post-mortem
tissue from temporal cortex was used. The level of
lysozyme was significantly increased in the AD group
(Braak stages V-VI) compared to controls (Braak
stages 0-IV) (Fig. 3B), which corresponds with the
lysozyme mRNA expression analysis. In addition,
lysozyme levels were investigated in an AD validated
cohort of CSF and the lysozyme levels were significantly higher in CSF samples from AD patients compared to controls (Fig. 3C).

A

Visual cortex

***

Prefrontal cortex

***

In order to study if lysozyme has any effect on Ab
toxicity, we used one Drosophila model where human
lysozyme was coexpressed with Ab1-42 and one,
recently characterized, novel Drosophila model that
coexpressed AbPP and BACE1 (AbPP–BACE1) [17]
with or without lysozyme in the eyes of the flies using
the retina-specific gmr-Gal4 driver. The eye morphology was examined at the day of eclosion using SEM.
Ab1-42 flies had a disturbed pattern of ommatidia compared to control flies (only expressing Gal4) and lysozyme flies (Fig. 4A,B). This disturbed ommatidia
phenotype was completely rescued when Ab1-42 was
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Fig. 3. Lysozyme is increased in brains from AD patients. (A) Lysozyme mRNA expression (LYZ; log-values of the mean intensities,
normalized to the average intensities of all samples) in the visual cortex, prefrontal cortex and cerebellum of healthy controls (C) (n = 173)
and AD patients (n = 376). Significant differences were determined by Student’s t-test; ***P ≤ 0.001. Bars represent mean  SEM. (B)
Representative western blot of human temporal cortex tissue from healthy controls (Braak 0-IV, n = 24) and AD patients (Braak V-VI,
n = 10). Shown are densitometric quantifications of the western blots, normalized to GAPDH levels and to a standard sample loaded on
each gel. Significant differences were determined by the nonparametric Mann–Whitney U test. Bars represent the mean  SD. (C)
Lysozyme concentrations in CSF from controls (n = 25) and biochemical and clinical diagnosed AD patients (n = 25) measured using the
Meso Scale Discovery technique. Significant differences was determined by Student’s t-test, *P ≤ 0.05. Bars represent the mean  SD.
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Fig. 4. Lysozyme protects transgenic AD flies from Ab-induced toxicity. (A) Images of rough eye phenotype obtained by scanning electron
microscopy of two AD Drosophila models expressing Ab1-42 or AbPP–BACE1 with or without lysozyme (Lys) and controls; only expressing
Gal4, AbPP and Lys at the day of eclosion (1509 magnification). Scale bars = 50 lm. (B) Quantification of the abnormal ommatidia seen in A
(n ≥ 4 of each genotype). All samples are related to their respective control. Significant differences were determined by one-way ANOVA
followed by Tukey’s test, **P ≤ 0.01, ***P ≤ 0.001. Meso Scale Discovery analyses performed on fly heads from flies at the day of eclosion
to quantify the levels of (D) soluble Ab1-42 (n = 4) and (E) insoluble Ab1-42 (n = 4). All samples are compared to their respective control.
Significant differences were determined by one-way ANOVA followed by Tukey’s test, **P ≤ 0.01, ***P ≤ 0.001. (C) Immunoprecipitation
assay of extract from AbPP–BACE1 flies with and without coexpression of lysozyme. Brain homogenates were immunoprecipitated with
lysozyme antibodies bound to resin and the urea-eluted samples were analysed for Ab1-42 using the Meso Scale Discovery technique. The
assay was performed on 100 flies of each genotype. Significant differences were determined by Student’s t-test, *P ≤ 0.05.

coexpressed with lysozyme (Fig. 4A,B). AbPP–BACE1
flies showed a heavily disturbed pattern of ommatidia
with fused and irregular-shaped ommatidia (Fig. 4A,
B), while flies that expressed AbPP demonstrated a
regular and symmetric pattern of ommatidia and
BACE1 flies exhibited a small disruption of the eye
phenotype (Fig. 4A,B). Coexpression of lysozyme with
the AbPP–BACE1 flies significantly rescued the disturbed ommatidia phenotype (Fig. 4A,B).
Lysozyme does not change the level of Ab but
binds to Ab in the Drosophila eye
Having established that lysozyme has a protective effect
in the AD transgenic flies, we next investigated if coexpression of lysozyme in these flies could change the level
of soluble and insoluble Ab1-42. The level of Ab1-42 in
the heads of the flies was measured by the Meso Scale
Discovery technique. There was a significant increase in
both soluble and insoluble levels of Ab1-42 in flies that
expressed Ab1-42 or AbPP and BACE1 compared to
their controls (only expressing Gal4 or AbPP respectively) (Fig. 4D,E). The proportion of insoluble and soluble Ab1-42 were compared in the flies and the level of
insoluble Ab1-42 was eight times higher than soluble
Ab1-42 in the Ab1-42 flies and the level of insoluble Ab142 was 40 times higher than soluble Ab1-42 in the AbPP–
BACE1-expressing flies. Coexpression of lysozyme in
the flies that expressed Ab1-42 or AbPP–BACE1 did not
change the soluble or insoluble level of Ab1-42 in the two
fly models (Fig. 4D,E). In order to investigate a potential interaction between Ab1-42 and lysozyme, an
immunoprecipitation assay was performed. Extract
from AbPP–BACE1 flies with and without coexpression
of lysozyme was run on a column with lysozyme antibodies bound to the resin. The urea-eluted samples were
analysed for Ab1-42 using the Meso Scale Discovery
technique. The AbPP–BACE1–lysozyme extract had a
significantly higher Ab1-42 signal compared to the Ab1-42
signal in the AbPP–BACE1 extract (Fig. 4C), which
indicates an interaction between Ab1-42 and lysozyme in
the AbPP–BACE1–lysozyme flies. Taken together, these
6

results demonstrate that the protective effect of lysozyme overexpression in the AD transgenic flies was not
due to changed levels of Ab1-42, but might instead
depend on interactions of Ab1-42 and lysozyme in the
AD fly eye.
Lysozyme rescues AbArc flies without changing
the level of AbArc
To further investigate the beneficial effects of lysozyme
on Ab-induced toxicity, a longevity assay was performed using a Drosophila model expressing Ab1-42
with the Arctic mutation (AbArc) with or without coexpressing human lysozyme in the fly CNS using the
elav-Gal4 driver. As seen in Fig. 5A, there was a dosedependent rescue mediated by lysozyme where the
median survival for AbArc flies was prolonged from 10
to 11 days for AbArc flies carrying one copy of lysozyme and from 10 to 12 days for AbArc flies carrying
two copies of lysozyme. Flies expressing both lysozyme
lines reduced the median survival for the control Gal4
expressing flies from 44 days to 41 and 39 days, line A
and line B respectively. Next, the velocity and angle of
movement were examined using the iFly technique
[18]. To study the effect of lysozyme on toxicity
induced by the AbArc peptide in adult flies, crosses
were set up using the lower temperature 18 °C, which
has been demonstrated to significantly lower protein
expression [19]. The flies were then moved to 29 °C
after eclosion to induce expression of AbArc as well as
lysozyme. The velocity of the flies will decrease as they
age or get sick. Shortly before the flies die, they
become immobile and their velocity cannot be
recorded; thus, a cut-off value of 4 mms 1 was set as
an indication of dysfunctional locomotor behaviour
[10]. The AbArc flies reached below this value after
9 days and after 10 days, no movement could be
recorded. For AbArc flies coexpressing one or two
copies of lysozyme, the cut-off value was reached after
12 and 15 days respectively, revealing a dose-dependent rescue effect of lysozyme on AbArc toxicity where
the dysfunctional locomotor behaviour of the AbArc

The FEBS Journal (2016) ª 2016 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies.

L. Sandin et al.

Lysozyme prevents Ab-toxicity

A

Control

Lys

Aβ1-42

Aβ1-42-Lys

AβPP

BACE1

AβPP-BACE1

AβPP-BACE1-Lys

**

8000
6000
4000

0

***

10

E1
C
BA

6

**
**

Aβ
PP

ns
100
80
40

insoluble A

p=0.95

0.05
0.04
0.03
0.02
0.01
0.00

-B

Aβ
P

8

E
(pg)

***

1-42/fly

ns
12

***

***

60
20

ns

0.6

**

0.4

***

0.2
0.0

flies was postponed 3 and 6 days (Fig. 5B). For control flies only expressing Gal4 and for flies expressing
one or two copies of lysozyme, the cut-off value was

ys
142
-L

Aβ

142

Aβ

BA
Aβ
PP
C
E1
-B
AC
E1
-L
ys

Aβ
PP
-

Ly
s

l
Aβ
PP

tro
C

on

ys

142

Aβ

142
-L

Aβ

ys
-L
E1

Aβ
PP
-

BA
C

AC
E1

Ly
s

-B
Aβ
PP

Aβ
PP

C

on

tro

l

soluble A

1-42/fly

(pg)

D

P-

Aβ

142

142
-L

BA
C
E1

on
C

ys

0

Aβ
Ly
PP
s
Aβ
-B
AC
PP
-B
E1
AC
E1
-L
ys
Aβ

2000

tro
l
Aβ
PP

10

ys

20

*

E1
-L

30

X/X;+/+;+/gmr
X/X;AβPP/+;+/gmr
X/X; +/+;BACE1/gmr
X/X;Lys/+;+/gmr
X/X;AβPP/+;BACE1/gmr
X/X;AβPP/Lys;BACE1/gmr
X/X;Aβ1-42/+;Aβ1-42/gmr
X/X;Aβ1-42/Lys;Aβ1-42/gmr

AC

Control
AβPP
BACE1
Lys
AβPP-BACE1
AβPP-BACE1-Lys
Aβ1-42
Aβ1-42

40

10 000

C

1-42 (a.u.)

50

% abnormal ommatidia

***

***
***
**

A

B

reached after 33, 27 and 28 days, respectively, revealing a detrimental effect of lysozyme on the locomotor
performance of the Gal4-expressing flies (Fig. 5B). The
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Fig. 5. Longevity and behavioural analyses show beneficial effects of lysozyme on AbArc flies. (A) Lifespan trajectories for Drosophila flies
expressing Ab with the Arctic mutation (AbArc) in the CNS, in the absence or presence of lysozyme expressed as one copy or as two copies
compared to control flies (n = 100). Kaplan–Meier graph shows per cent survival against age of flies in days after eclosion. Significant
differences were determined by log-rank analysis, *P ≤ 0.05 and ***P ≤ 0.001. The fly behaviour was analysed for control flies and AbArc flies
with or without coexpression of one or two copies of lysozyme by (B) velocity measurement, (C) velocity measurement at day 9, (D) angle of
movement analysis and (E) angle of movement analysis at day 6. Significant differences were determined by one-way ANOVA followed by
Tukey’s test, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. Error bars represent mean  SD, n = 30. (F) Meso Scale Discovery analysis performed on
the fly heads of control, AbArc, AbArc-Lys and AbArc-Lys-Lys at day 10 after eclosion to quantify the levels of soluble and insoluble AbArc.
Significant differences were determined by one-way ANOVA followed by Tukey’s test, ***P ≤ 0.001. Error bars represent mean  SD, n = 4.

AbArc flies coexpressing one or two copies of lysozyme
had a significantly higher velocity compared with the
AbArc flies at day 9 (Fig. 5C).
The angle of movement increases as the flies age or
get sick and a cut-off value of 80° was set in order to
indicate dysfunction of the flies’ locomotor behaviour
[10]. In the angle of movement analysis, AbArc flies
reached above 80° after 6 days, while AbArc flies with
one or two copies of lysozyme both reached above this
value after 10 days (Fig. 5D). Control Gal 4 flies and
flies coexpressing one or two copies of lysozyme did
not display this dysfunction, all genotypes reached
above the cut-off value after 18 days. The AbArc flies
coexpressing one or two copies of lysozyme had a significantly lower angle of movement compared with the
AbArc flies at day 6 (Fig. 5E).
In order to investigate whether coexpression of one
or two copies of lysozyme in the AbArc flies had any
effect on the levels of soluble and insoluble AbArc, the
level of AbArc was measured in the head of the flies
using the Meso Scale Discovery technique after ageing
the flies for 10 days at 29 °C after eclosion. The soluble levels of AbArc were low and no significant differences were detected between the different fly variants
(Fig. 5F). When analysing the insoluble levels of
AbArc, significant levels were detected in all AbArc
expressing flies compared to control Gal4 flies coexpressing two copies of lysozyme (Fig. 5F). No significant differences were detected between AbArc flies and
flies coexpressing the AbArc peptide with one or two
copies of lysozyme (Fig. 5F). Taken together, these
data show that lysozyme had a dose-dependent rescue
effect on the AbArc toxicity when lysozyme expression
was directed to the CNS, lysozyme increased the median survival and decreased dysfunctional locomotor
behaviour observed for the AbArc flies, without changing the levels of soluble or insoluble AbArc.

Discussion
Previously, it was demonstrated that lysozyme is associated with Ab-plaques in human brain tissue [10].
This study demonstrates that both mRNA and protein
8

levels of lysozyme were upregulated in AD mouse
models and in human AD cases and that lysozyme
associated with Ab-plaques in mice brain tissue. In the
AD transgenic mouse models, hippocampus and cortex, but not cerebellum, displayed increased mRNA
expression of lysozyme compared to WT mice. A similar lysozyme mRNA profile was detected in humans,
with increased lysozyme expression in visual cortex
and prefrontal cortex in AD patients, and again, no
apparent change in cerebellum. The spread of Ab
pathology starts in the areas of cortex and hippocampus and does not affect the cerebellum until late in the
disease in both AD mouse models and AD patients
[20–22]. In this study, a similar pattern of lysozyme
expression was revealed both in the AD mouse models
and AD patients. The expression of lysozyme in the
cortex and hippocampus of AD transgenic mice correlated well with Ab pathology and the Ab pathology
had a spatial similarity with the increase of lysozyme
expression. It was recently shown that exposure of
neuroglia cells to oligomeric Ab causes an intracellular
upregulation of lysozyme as well as an increased secretion of lysozyme [10]. Increased lysozyme protein levels
were found in the cortex of PS1 and AbPPSwe transgenic mice and in the temporal cortex of human AD
patients. An increased level of lysozyme was also
detected in CSF from AD patients. This was previously seen in two cohorts of CSF of biochemical diagnosed AD patients [10]. The CSF cohort used in this
study was from both clinical and biochemical diagnosed AD patients. It is likely that the increased
mRNA expression in affected brain regions gave rise
to increased protein expression and was responsible
for the increased protein level of lysozyme seen in CSF
from AD patients. Thus, these in vivo and cellular
results suggest that Ab triggers an increase of lysozyme
expression and secretion. The expression of lysozyme
in tau transgenic mice did not correlate with the agerelated increase in tangle load, as demonstrated by the
sigmoidal relationship between levels of Ab and lysozyme. Tau pathology was increased at 8 months in the
tau transgenic mice, both in cortex and hippocampus,
but the increase in lysozyme did not appear until after

The FEBS Journal (2016) ª 2016 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies.

L. Sandin et al.

Lysozyme prevents Ab-toxicity

Control ( XElav/X;+/+;+/+)
LyslineA ( XElav/X;+/+;+/LyslineA)

80

***
***

LyslineB ( XElav/X;+/LyslineB;+/+)
AβArc ( XElav/X;AβArc/+;+/+)

40

AβArc-Lys ( XElav/X;AβArc/+;+/LyslineA)
AβArc-Lys-Lys ( XElav/X;AβArc/LyslineB ;+/LyslineA)

***

60

*

***

Percent survival

A 100

20
0
0

5

10

15

20 30 40 50 60

Days post eclosion
Control
Lys

15

Lys-Lys
AβArc

10

AβArc-Lys
AβArc-Lys-Lys

5

C

20

Velocity (mm·s–1)

15
10

***

**

5

ys

-L

ys
-L

rc

-L

rc

A
β

F

***
***

(pg)

80

Arc/fly

C

Days post eclosion

A

0

ys

30

-L

25

ys

20

-L

15

Ar
c

10

ys

5

tro
l

0

-L

40

20

rc

60

40

rc

AβArc-Lys-Lys

60

βA

AβArc-Lys

A
βA

AβArc

80

**

80

A

Lys-Lys

Ly
s

100

Ly
s-

Control
Lys

*

100

Ly
s

E
120

on

Angle of movement (degrees)

D

Angle of movement (degrees)

A
βA

C

Days post eclosion

c

35

A
βA

30

Aβ
Ar

25

Ly
s

20

Ly
s-

15

l

10

tro

5

on

0

ys

0

0

Ly
s

Velocity (mm·s–1)

B 20

ns
ns

60

***

Soluble
Insoluble

40
20

c

-L Lys
ys
-L
ys
C
on
tro
l
Aβ
A
A
r
βA c
A
βA rc-L
ys
rc
-L
ys
-L
ys

rc

Aβ

Ar
c

A
βA

tro
C
on

Aβ
Ar

l

0

The FEBS Journal (2016) ª 2016 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies.

9

L. Sandin et al.

Lysozyme prevents Ab-toxicity

18 months. These results agree with the previous findings in the AD transgenic mouse models that amyloid
plaque pathology correlates with overexpression of
several immune genes, whereas this correlation was
not found for the tau transgenic mouse model [15].
It was previously shown that lysozyme is able to
rescue a Drosophila AD model where Ab1-42 and
lysozyme were expressed and secreted, using a secretion tag, in the CNS of the flies [10]. In this study,
the Ab1-42 production was targeted to the retina of
the flies by use of the gmr-Gal4 driver. The benefit of
this driver is that the eye is a nonessential organ for
fly survival, and products from transgenes that interfere with ommatidia development can easily be visualized in the fly eye as a rough eye phenotype.
Moreover, in this study, we further investigated the
effect of lysozyme on Ab toxicity by introducing a
new AD model where the Ab peptide was generated
by the processing of AbPP with b-secretase followed
by c-secretase. This new AD fly model is more physiological relevant and produces Ab of various lengths
[17]. Flies that expressed Ab1-42 and flies that coexpressed AbPP and BACE1 had defects in the ommatidia structure. This phenotype was completely
abolished when lysozyme was coexpressed, resulting
in fly eyes with well-ordered ommatidia similar to
control flies. Thus, in both AD models, the eye phenotype was rescued by coexpression of lysozyme
which demonstrates that lysozyme was able to exert
its antitoxic effect, both when the Ab peptide was
expressed directly from the transgene and when it
was generated by AbPP processing. In addition, the
rescue effect of lysozyme on the AbPP–BACE flies
reveals possible interactions of lysozyme with several
Ab species generated in these flies.
In addition, we report that lysozyme also had a
dose-dependent protective effect on the Arctic mutation of Ab1-42, when expressed in the CNS of the flies.
The Arctic mutation of Ab1-42 leads to an increased
propensity of Ab to form oligomeric species and at a
faster rate [23]. One copy of lysozyme increased the
median survival of flies expressing AbArc with 1 day,
and two copies extended the median survival with
2 days. To achieve a more complete picture of the
health of the flies, a locomotor assay was used to
study the velocity and the angle of movement of flies
expressing the AbArc peptide alone or together with
one or two copies of lysozyme. Coexpression of both
one and two copies of lysozyme demonstrated beneficial effects on both the velocity and angle of movement of the AbArc flies, which proves that lysozyme
has the ability to decrease locomotor disability caused
by the AbArc peptide.
10

The rescue effect of lysozyme on AbArc toxicity in
the longevity and locomotor assays cannot be attributed to a general beneficial effect of the fly health by
expressing lysozyme in the fly CNS as flies only
expressing lysozyme showed a reduction in the median
survival time compared to Gal4 control flies (by
approximately 4 days). A detrimental effect was also
detected in the velocity experiment for lysozyme
expressing flies compared to the Gal4 flies, while no
general effect of lysozyme was detected in the angle of
movement analysis of Gal4 flies. Altogether, these
results demonstrate that lysozyme has a protective
effect on Ab-induced toxicity.
One possible explanation for the protective action of
lysozyme could be that it increases the degradation of
the Ab peptide in the flies. This was shown in a study
where coexpression of lysozyme in Ab1-42 transgenic
Drosophila increased the survival of the flies and
reduced the levels of Ab1-42 [10]. However, in this
study, there was no difference in the amount of either
soluble or insoluble Ab1-42 between flies that expressed
Ab1-42 or Ab1-42 coexpressed with lysozyme, or AbPP–
BACE1 flies and flies with AbPP–BACE1 and lysozyme. The discrepancies between these studies are that
in the previous study, Ab1-42 and lysozyme were
expressed in the CNS but in this study, the expression
was targeted to the eyes of the flies. The degradative
capacity of Ab1-42 in the brain and eye can be different
and lysozyme can interact with Ab1-42 in another fashion in the brain compared with the eye, which might
explain the discrepancies between the results.
We have previously shown in vitro that lysozyme
binds to monomeric Ab1-42 and prevents the formation of toxic Ab1-42 species by reducing the aggregation propensity of Ab1-42 [10]. Other studies have
shown that lysozyme also inhibits the aggregation of
Ab1-40 and Ab17-42 by binding during the early stages
of fibrillation, thereby reducing toxic species and
cytotoxicity [11,12,24]. We have also reported that
lysozyme colocalizes with Ab plaques in human AD
brain and with Ab aggregates in Ab-overexpressing
Drosophila flies [10]. In this study, we show that lysozyme stains plaques in AbPP mice which indicate that
fibrillar Ab and lysozyme are in close association. To
investigate if lysozyme was able to bind Ab in the
gmr-Gal4-derived flies, immunoprecipitation capturing
lysozyme was performed on fly head homogenates
followed by Meso Scale Discovery, where Ab was
detected with the 6E10 antibody. Indeed, there was a
significant increase of Ab1-42 in the homogenates from
AbPP–BACE1–lysozyme flies compared with the
AbPP–BACE1 flies. This demonstrates that also in
this Drosophila model lysozyme was able to interact
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with Ab and thus likely rescues the degeneration of
the ommatidia in the fly eye by preventing the formation of cytotoxic Ab species.
When quantifying the soluble and insoluble levels of
AbArc in the fly CNS, only insoluble Ab species were
detected and no significant differences could be
observed between the insoluble levels in flies, solely
expressing AbArc, and in flies where AbArc was coexpressed with one or two copies of lysozyme. Hence,
the protective properties of lysozyme in the longevity
and locomotor analyses of the AbArc flies must be
unrelated to degradation of AbArc. A possible explanation for the antitoxic effect of lysozyme in the AbArc
flies could be due to interactions between the insoluble
AbArc species and lysozyme reducing the toxicity of
these species. The Arctic mutation causes the Ab1-42
peptide to be more aggregation prone and therefore
less prone to be degraded. This might explain why
lysozyme overexpression in the CNS of AbArc flies was
unable to cause an increased degradation of Ab, which
earlier was suggested for lysozyme overexpression in
the CNS of Ab1-42 flies [10].
In conclusion, we show that the expression of lysozyme was increased in the brains of both transgenic
AD mice and humans with AD. Furthermore, we
demonstrate favourable effects of lysozyme when
expressed in different Drosophila models of AD. In
flies that expressed Ab1-42 or AbPP together with
BACE1 in the eyes, the rough eye phenotype indicative
of toxicity was completely rescued by coexpression of
lysozyme. In Drosophila flies that express the toxic
AbArc, lysozyme both increased the fly survival dose
dependently and decreased dysfunction in locomotor
behaviour. We propose that this is due to binding of
lysozyme to toxic species of Ab which prevent these
from exerting their toxic effect. Thus, the upregulated
of lysozyme expression in AD patients and transgenic
AD mice might be a rescue response towards Ab toxicity. These results highlight the possibility of lysozyme
as a potential therapeutic target for AD.

Lysozyme prevents Ab-toxicity

was used to study the lysozyme expression in 101 nondemented healthy controls and 129 AD patients (GEO accession number GSE44772) [16].

Protein extraction from brain tissue
Human brain tissue were obtained from the Sydney Brain
Bank at Neuroscience Research Australia and the New
South Wales Tissue Resource Centre at the University of
Sydney and characterized according to established neuropathological criteria [25]. Informed consent for the collection of material was obtained prior to death and tissue use
was approved by the University of New South Wales
Human Research Ethics Committee. Brain biopsies from
34 cases (Braak stages 0-VI) from temporal cortex were
frozen with a post-mortem delay of maximum 64 h. The
tissues were homogenized in 4 lLmg 1 sample of cold
TBS [50 mM TRIS, 125 mM NaCl, 5 mM EDTA, protease
inhibitor (Roche, Basel, Switzerland)] using a motorized
pestle prior to centrifugation at 20 800 g at 4 °C for 1.5 h.
The APP-PS1 AD mouse model expressing chimeric
mouse/human APP695swe/Swedish mutations (K595N/
M596L) and mutant human PS1 (PS1/ΔE9) was obtained
from the Jackson Laboratory (Bar Harbor, ME, USA;
Strain name, B6.Cg-Tg AbPPswePSEN1dE9) 85Dbo/J;
Stock #005864). Animal ethics approval was from the
University of Wollongong Animal Ethics Committee (AE11/
03). The mice were aged for 12 months without any intervention; food and water were available ad libitum. In brief, 12month-old APP-PS1 and age-matched wild-type mice were
euthanized by CO2 asphyxiation to ensure that the mice did
not suffer unnecessarily, and transcardially perfused with
ice-cold phosphate-buffered saline (PBS). The right hemisphere from the APP-PS1 and age-matched wild-type mice
were snap frozen and stored at 80 °C. Cortex was dissected
and homogenized in 10 volumes of 140 mM NaCl, 3 mM
KCl, 25 mM Tris (pH 7.4), containing 1% Nonidet P-40 and
Roche complete protease inhibitors using a Precellys 24
homogenizer (2 9 30 s, 6000 g). The supernatants were
saved and the protein concentration was determined using a
DC protein assay (Bio-Rad, Hempstead, UK).

CSF cohort

Materials and methods
Gene expression studies
The database (www.mouseac.org) which includes microarray data from amyloid transgenic mice carrying the
AbPPSwe mutation and/or PSEN1 (PSEN1: M146V) either
heterozygous or homozygous, and tau transgenic mice
(TAU: P301L) [15], was used to study lysozyme mRNA
expression and pathology during ageing (GEO accession
number GSE64398). In addition, a microarray data set
containing information about human mRNA expression

Deidentified and archived CSF samples, that were both
biochemically and clinically diagnosed with AD (n = 25),
were age- and gender-matched with controls with normal
levels of the CSF AD biomarkers P-tau181P, T-tau and
Ab1-42 (n = 25). The samples were provided by the Clinical
Neurochemistry Laboratory, Sahlgrenska University
Hospital/M€
olndal, Sweden. The study was approved by the
Ethical committee at the University of Gothenburg. For
more information regarding CSF handling and P-tau181P,
T-tau and Ab1-42 analysis, see previously described
methods [26].
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Western blotting
Protein separation was performed as described previously
[26]. Forty microgram of total protein was mixed with loading buffer and blotted onto a nitrocellulose membrane using
an iBlot Dry Blotting System (Invitrogen, Paisley, UK) and
incubated with polyclonal rabbit anti-human lysozyme antibody (1 : 2000) (Dako, Glostrup, Denmark) overnight in
4 °C, followed by horseradish peroxidase (HRP)-linked goat
anti-rabbit antibody (Dako) for 1 h at room temperature.
Mouse anti-glyceraldehyde-3-phosphate dehydrogenase
(GAPDH; 1 : 20 000; Novus Biologicals, Littletown, CO,
USA) was used as loading control. To correct for differing
protein levels between blots, all samples were normalized to
a reference sample, which was loaded onto each gel.

Immunohistochemistry
C57Bl/6 transgenic AbPPSwe mice (kindly provided by Professor Lars Nilsson at Oslo University) were housed in a
pathogen-free environment on a 12-h light/dark cycle. The
mice were aged for 15 months without any intervention;
food and water were available ad libitum. The experimental
procedures were performed in accordance with the Animal
Care and Use Ethical Committee at the Link€
oping University (ethical registration number 84-12) which follow the
directives 2010/63/EU of the European Parliament and of
the Council of 22 September 2010 on the protection of animals used for scientific purposes. The mice were euthanized
by CO2 asphyxiation to ensure that the mice did not suffer
unnecessarily, and transcardially perfused with saline solution (NaCl, 0.9%) before dissection of the brain. The brain
tissue were stored in formalin, dehydrated in sucrose, sectioned and frozen. Immunohistochemistry was performed
according to the manufacturer’s protocol (Biocare Medical,
Concord, CA, USA). Ab plaques were immunostained
using the 6E10 antibody (1 : 100; Signet Laboratories/Covance, Dedham, MA, USA), then colour was developed
using diaminobenzidine (DAB; Biocare Medical) and lysozyme was immunostained with an anti-lysozyme antibody
(1 : 100; Dako) and colour was developed with Vina
GreenTM Chromogen Kit (Biocare Medical). To stop crossreaction, the brain slices were incubated with denaturing
solution (Biocare Medical) for 5 min before double staining
with lysozyme antibody.

Drosophila stocks
To direct tissue-specific protein expression in UAS transgenic Drosophila melanogaster, the Gal4/UAS system was
used [27]. In the SEM analysis, the tissue-specific gmr-Gal4
driver strain was used to direct protein expression to the
photoreceptors present in the retina of the flies [28]. Control w1118 flies (only expressing Gal4), AbPP695 (AbPP) and
BACE1-expressing flies were purchased from Bloomington

12

stock centre. Signal-peptide-Ab1-42 flies and signal-peptideAbArc (E22G) were kindly provided by Professor Damian
Crowther [29]. Lysozyme-expressing flies were constructed
as described previously [30]. To generate flies coexpressing
Ab1-42 or AbPP–BACE1 together with lysozyme or flies
coexpressing AbArc with either one or two copies of WT
lysozyme, cross-breeds were set up in multiple steps with
12:12 h light:dark cycles and 60% humidity. In the longevity and locomotor analyses, the elav-Gal4 driver line was
used to direct protein expression to the fly CNS. To generate XElav/Y;AbArc/Ife;TM6b/+, a cross was set up using
XElav/XElav;CyO/Ife;TM6b/mkrs and X/Y;AbArc/AbArc;+/+.
In order to achieve coexpression of AbArc with one or two
copies of lysozyme, males generated in the cross previously
described were crossed with X/X;LyslineB/LyslineB;+/+ or X/
X;LyslineB/LyslineB;LyslineA/TM6b. All gene constructs of
lysozyme and AbArc where cloned into the Gal4-responsive
pUAST expression vector to generate UAS-lysozyme or
UAS-arctic transgene. These constructs were injected into
the same background W1118 flies [29,30].

SEM of eye phenotype
Cross-breeds were set up at 25 °C. At the day of eclosion,
flies were euthanized with ether before they were mounted
onto 12-mm aluminium specimen stubs with an adhesive
tape and air-dried for 24 h. The samples were sputter
coated with 15 nm of platinum and stored in a vacuum
desiccator prior to analysis using SEM (JEOL JSM-6320F).
The eyes were scanned at 1509 magnification at an accelerating voltage of 10 kV. Images were recorded using the
SemA for 5.21 digitizer system (Insinooritoimisto Rimppi
Oy). In a blinded set-up, the images were printed and
assigned a square of approximately 100 ommatidia in the
centre of the eye. All abnormal ommatidia were quantified
within this square and further related to all ommatidia.

Sample preparation for Ab1-42 quantification
Cross-breeds were set up at 25 °C. Flies were snap frozen
in liquid nitrogen at the day of eclosion. Approximately, 20
heads per genotype were homogenized in 120-lL soluble
extraction buffer [50 mM Hepes, 5 mM EDTA, protease
inhibitor (Complete EDTA-free Protease Inhibitor Cocktail
Tablets, Roche Diagnostic)] for the soluble fraction of Ab1-42.
After homogenization, the samples were centrifuged for
5 min, 16 000 g. The supernatant was then collected in an
Eppendorf tube. The pellet was rehomogenized in 25-lL
insoluble extraction buffer (50 mM Hepes, 5 mM EDTA,
5 M guanidinium chloride, protease inhibitor) for the insoluble fraction of Ab1-42. After homogenization, the samples
were incubated at RT for 10 min, followed by sonication in
a water bath for 4 min. The samples were then centrifuged
for 10 min, the supernatant of the insoluble fraction was
collected and diluted 1 : 10 in Diluent 35 (R50AE-2, Meso
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Scale Discovery, Rockville, ML, USA). The samples were
stored at 80 °C. To account for differences in the protein
extraction step, the total amount of protein extracted was
quantified using the Bio-Rad DC Protein Assay Kit II
(500-0112, Bio-Rad).

Quantification of Ab1-42 by Meso Scale Discovery
analysis
The wells in a multi-spot 96-well V-PLEX human Ab1-42
(K151LBE-1, Meso Scale Discovery) were blocked using 150lL Diluent 35 for 1 h at RT with gentle agitation. After blocking, 50 lL of each prepared protein sample was added to the
wells in duplicates (incubated 1 h, RT, gentle agitation). After
sample incubation, the wells were washed in 3 9 150 lL
PBS-T before adding 25 lL of the detection antibody (509
Sulfo tag 6E10, Meso Scale Discovery) (1 h, RT, gentle agitation). The wells were then washed again (3 9 150 lL PBS-T)
before adding 150 lL 29 read buffer (10 min incubation, RT,
no agitation). The plate was analysed using a SECTOR Imager 2400 instrument (Meso Scale Discovery).

Sample preparation and quantification of AbArc
by Meso Scale Discovery
Fly crosses were set up at 18 °C and at the day of eclosion
moved to 29 °C where they were aged for 10 days. After
ageing, 10 fly heads of each genotype were placed in
Eppendorf tubes and stored at –80 °C until use. The Meso
Scale Discovery analysis was performed as previously
described by Caesar et al. [31]. To account for any differences in the protein extraction step, the total amount of
protein extracted for each sample was quantified using the
Bio-Rad DC Protein Assay Kit II (500–0112, Bio-Rad).

Longevity assay
Fly crosses using the elav-Gal4 driver were set up at 29 °C
and maintained at 29 °C (60% humidity, 12:12 h dark:light
cycle) after eclosion. A set of 100 female offspring for each
genotype was collected at the day of eclosion. The flies
were then divided into groups of approximately 10 flies and
placed in vials containing agar food (20 g agar, 20 g
sugarL 1 dH2O) and yeast paste (dry baker’s yeast mixed
with water). Every 2–3 day, the flies were transferred to
vials containing fresh food and the number of living flies
was counted. This was repeated until all flies had died.
Kaplan–Meier survival curves were generated for lifespan
assessment.

Locomotor assay
Fly crosses were set up at 18 °C and at the day of eclosion,
moved to 29 °C. Sets of 30 female flies of each genotype

Lysozyme prevents Ab-toxicity

were collected and divided into groups of 10 and placed in
vials containing fly food. To analyse the flies’ locomotor
behaviour, the flies were filmed during 90 s and tapped to
the bottom of the vial every 30 s to reactivate locomotor
behaviour. This was carried out every day until all AbArcexpressing flies had stopped to move; the Gal4- and lysozyme-expressing flies were analysed every other/third day
until no locomotor behaviour could be detected for these
fly variants. The videos were processed and analysed using
the IFLY software [18], which calculated the velocities and
angles of movement generated by the flies in each recorded
video clip. The locomotor measurements were carried out
as described previously [17].

Immunoprecipitation
Lysozyme-specific capture resin was prepared as described
earlier [30] with CNBr-activated Sepharose 4B resin (GE
Healthcare, Pittsburgh, PA, USA) and 0.5 mgmL 1 polyclonal rabbit anti-human lysozyme (Dako; A0099). One
hundred microlitre of the anti-lysozyme conjugated medium
slurry was placed in a Micro Bio-Spin Chromatography
Column (Bio-Rad) and the column was equilibrated with
SuperBlock TBS Blocking Buffer (Thermo Scientific Pierce,
Rockville, IL, USA) supplemented with a protease inhibitor
(TBS-PI). Heads from AbPP flies, AbPP–BACE flies and
AbPP–BACE flies with lysozyme were homogenized with a
pestle in 200 lL TBS-PI and centrifuged for 1 min at
16 000 g. One hundred flies of each genotype were used.
The supernatant was centrifuged a second time before incubation in the column for 5 min and centrifuged 160 g for
1 min. The resin was then washed four times with TBS-PI
before lysozyme was eluted with 6 M urea. The concentration of Ab1-42 was measured using the Meso Scale Discovery technique, as described above.

Statistical analysis
All statistical analyses and graphs were performed and
drawn using GRAPHPAD PRISM software v. 7 (GraphPad Software, La Jolla, CA, USA). Two-way ANOVA followed by
Tukey’s post hoc test was used to test for significant differences between multiple groups of mice. Correlation analysis
was performed using the Pearson correlation coefficient.
One-way ANOVA followed by Tukey’s test was used for
quantification of abnormal ommatidia and to test for differences in protein levels analysed with the Meso Scale Discovery technique. Student’s t-test or Mann–Whitney U test
was used to test for significant differences between two
groups. For the lifespan assay, Kaplan–Meier survival
curves were generated and log-rank statistical analysis
(Mantel–Cox) was performed. Statistical significance was
defined for P-values of < 0.05 (*), < 0.01 (**) and < 0.001
(***).
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